Home > Haematology > EHA 2019 > Myeloid Malignancies > Residual disease in AML patients prior to stem cell transplant increases relapse risk

Residual disease in AML patients prior to stem cell transplant increases relapse risk

Presented By
Dr Christopher Hourigan, NIH, USA
Conference
EHA 2019
For patients with acute myeloid leukaemia (AML), the presence of measurable residual disease (MRD) prior to stem cell transplant significantly increases the risk of relapse among patients who receive a reduced-intensity conditioning regimen, compared with those with no MRD. This suggests that patients with evidence of MRD should receive higher-intensity conditioning, say researchers reporting a new analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 [1]. In the late-breaking abstracts session, Dr Christopher Hourigan (NIH, USA) presented the results of preconditioning samples from 188 AML patients in the 0901 trial. The patients were well matched with respect to baseline characteristics, including age, sex, disease risk, donor type, donor match, and graft type. A previous analysis of this study compared the outcomes of AML pa...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on